| Induction of chronic lymphocytic leukemia-like disease in STYK1/NOK transgenic mice. | Induction of chronic lymphocytic leukemia-like disease in STYK1/NOK transgenic mice.
Yang Y, Liu L, Tucker HO. | 09/24/2022 |
| NOK associates with c-Src and promotes c-Src-induced STAT3 activation and cell proliferation. | NOK associates with c-Src and promotes c-Src-induced STAT3 activation and cell proliferation.
Wang Y, Liu S, Jiang G, Zhai W, Yang L, Li M, Chang Z, Zhu B. | 10/23/2021 |
| STYK1 promotes the malignant progression of laryngeal squamous cell carcinoma through targeting TGF-beta1. | STYK1 promotes the malignant progression of laryngeal squamous cell carcinoma through targeting TGF-β1.
Li XL, Huang YY, Yuan TJ, Lian XP, Bi HL. | 04/24/2021 |
| SMAD3 induces the transcription of STYK1 to promote epithelial-mesenchymal transition and to elicit paclitaxel resistance of ovarian cancer cells. | SMAD3 inducing the transcription of STYK1 to promote the EMT process and improve the tolerance of ovarian carcinoma cells to paclitaxel.
Shi Y, Zhang J, Liu M, Huang Y, Yin L. | 07/25/2020 |
| elevated serine threonine tyrosine kinase 1 (STYK1) or decreased serine peptidase inhibitor Kunitz type 2 (SPINT2/HAI-2) expression significantly correlated with poor prognosis, tumor invasion, and metastasis of NSCLC patients. STYK1 overexpression promoted NSCLC cells proliferation, migration, and invasion. STYK1 also induced epithelial-mesenchymal transition by E-cadherin downregulation and Snail upregulation. | STYK1 promotes tumor growth and metastasis by reducing SPINT2/HAI-2 expression in non-small cell lung cancer.
Ma Z, Liu D, Li W, Di S, Zhang Z, Zhang J, Xu L, Guo K, Zhu Y, Han J, Li X, Yan X., Free PMC Article | 07/11/2020 |
| Data suggest that regulating ferroptosis could be another cancerous mechanism of serine/threonine/tyrosine kinase 1 (STYK1). | STYK1/NOK correlates with ferroptosis in non-small cell lung carcinoma.
Lai Y, Zhang Z, Li J, Li W, Huang Z, Zhang C, Li X, Zhao J. | 06/27/2020 |
| findings suggest that STYK1 is a critical regulator of tumor growth and metastasis. | STYK1 promotes cancer cell proliferation and malignant transformation by activating PI3K-AKT pathway in gallbladder carcinoma.
Hu YP, Wu ZB, Jiang L, Jin YP, Li HF, Zhang YJ, Ma Q, Ye YY, Wang Z, Liu YC, Chen HZ, Liu YB. | 01/19/2019 |
| Overexpression of STYK1 was significantly associated with increased cell proliferation, migratory capability, and invasive capability in vitro, as well as increased volume of tumor, weight of tumor, and number of pulmonary metastasesin hepatocellular carcinoma. | STYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling.
Wang Z, Qu L, Deng B, Sun X, Wu S, Liao J, Fan J, Peng Z., Free PMC Article | 06/2/2018 |
| STYK1 plays an important role in glioma development and progression. | Knockdown of Serine Threonine Tyrosine Kinase 1 (STYK1) Inhibits the Migration and Tumorigenesis in Glioma Cells.
Zhou J, Wang F, Liu B, Yang L, Wang X, Liu Y., Free PMC Article | 03/31/2018 |
| Findings show that serine-threonine-tyrosine kinase 1 (NOK) mediates glycolysis and nuclear pyruvate dehydrogenase complex (PDC) associated histone acetylation. | NOK mediates glycolysis and nuclear PDC associated histone acetylation.
Shi WY, Yang X, Huang B, Shen WH, Liu L. | 09/2/2017 |
| Survival analysis reveals that STYK1 level is an independent prognostic factor for nasopharyngeal carcinoma patients. Our results indicate that STYK1 is a promising therapeutic target in nasopharyngeal carcinoma | STYK1 promotes Warburg effect through PI3K/AKT signaling and predicts a poor prognosis in nasopharyngeal carcinoma.
Zhao Y, Yang L, He J, Yang H. | 07/29/2017 |
| Thus, our results reveal a novel tumorigenic function of NOK to mediate the genesis and remodeling of blood and lymphatic vessels during tumor progression. | NOK/STYK1 promotes the genesis and remodeling of blood and lymphatic vessels during tumor progression.
Liu Y, Li T, Hu D, Zhang S. | 05/27/2017 |
| High STYK1 expression is associated with intrahepatic cholangiocarcinoma. | Depletion of STYK1 inhibits intrahepatic cholangiocarcinoma development both in vitro and in vivo.
Chen MY, Zhang H, Jiang JX, Sun CY, Yu C, Tian S. | 03/4/2017 |
| increased STYK1 protein expression correlates with disease progression and metastasis and may serve as a predictor of poor survival in CRC. | Serine threonine tyrosine kinase 1 is a potential prognostic marker in colorectal cancer.
Hu L, Chen HY, Cai J, Zhang Y, Qi CY, Gong H, Zhai YX, Fu H, Yang GZ, Gao CF., Free PMC Article | 07/2/2016 |
| The data indicates that both P203 and V395 residues on NOK are important for NOK mediated mitogenic signaling. | NOK mediated mitogenic signaling is altered by P203L and V395I mutations.
Hou SQ, Liu L. | 05/14/2016 |
| NOK expression increased in renal cell carcinoma and was significantly correlated with TNM stage, Fuhrman grade, poor overall survival, poor disease-free survival, metastasis, and proliferation. | High Novel Oncogene with Kinase-Domain (NOK) Gene Expression is Associated with the Progression of Renal Cell Carcinoma.
Cao Q, Chen M, Li Z, Huang W, Jin Y, Ye X, Tong M. | 04/23/2016 |
| STYK1/NOK is dramatically upregulated in colorectal cancer tissues and could be used as a tumor marker. Furthermore, the high expression of STYK1/NOK is significantly associated with tumor size. | Diagnostic relevance of overexpressed serine threonine tyrosine kinase/novel oncogene with kinase domain (STYK1/ NOK) mRNA in colorectal cancer.
Orang AV, Safaralizadeh R, Hosseinpour Feizi MA, Somi MH. | 06/20/2015 |
| These results suggest that STYK1 is a novel drug resistance factor and could be a predictor of the therapeutic response in acute leukemia. | Significance of serine threonine tyrosine kinase 1 as a drug resistance factor and therapeutic predictor in acute leukemia.
Nirasawa S, Kobayashi D, Kondoh T, Kuribayashi K, Tanaka M, Yanagihara N, Watanabe N. | 05/30/2015 |
| Our results indicate that NOK expression is of clinical significance and can serve as a prognostic biomarker in non-small cell lung cancer. | Clinicopathologic features and prognostic implications of NOK/STYK1 protein expression in non-small cell lung cancer.
Chen P, Li WM, Lu Q, Wang J, Yan XL, Zhang ZP, Li XF., Free PMC Article | 12/20/2014 |
| SuRTK106/NOK/STYK1 was first identified, classified and shown to have predicted pseudokinase domain. | The protein kinase complement of the human genome.
Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. | 04/2/2013 |
| The expression levels of NOK, p-Akt(Thr308) and p-GSK-3beta(Ser9) were positively correlated in cancerous and non-cancerous breast cell lines. | NOK/STYK1 interacts with GSK-3β and mediates Ser9 phosphorylation through activated Akt.
Li J, Wu F, Sheng F, Li YJ, Jin D, Ding X, Zhang S. | 01/5/2013 |
| Taken together, NOK has a strong tendency towards forming aggregates, which may have physiological implications and provide the first evidence that this novel receptor kinase is colocalised with EGFR in endosomes to participate in a post-internalisation step of EGFR. | NOK/STYK1 has a strong tendency towards forming aggregates and colocalises with epidermal growth factor receptor in endosomes.
Ding X, Jiang QB, Li R, Chen S, Zhang S. | 11/24/2012 |
| Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator) | Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score.
Rose JE, Behm FM, Drgon T, Johnson C, Uhl GR., Free PMC Article | 06/30/2010 |
| Overexpression of the potential kinase serine/ threonine/tyrosine kinase 1 (STYK 1) in castration-resistant prostate cancer. | Overexpression of the potential kinase serine/ threonine/tyrosine kinase 1 (STYK 1) in castration-resistant prostate cancer.
Chung S, Tamura K, Furihata M, Uemura M, Daigo Y, Nasu Y, Miki T, Shuin T, Fujioka T, Nakamura Y, Nakagawa H., Free PMC Article | 01/21/2010 |
| results indicate that STYK1/NOK mRNA is widely expressed in the patients with acute leukemia and suggest that inhibition of this molecule could potentially serve as a novel therapeutic target | Overexpression of serine threonine tyrosine kinase 1/novel oncogene with kinase domain mRNA in patients with acute leukemia.
Kondoh T, Kobayashi D, Tsuji N, Kuribayashi K, Watanabe N. | 01/21/2010 |